LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Highlights Democratising AI and Strengthening Trust in 2025 Sustainability Report11.5.2026 11:17:00 CEST | Press release
Company now provides global account services to 1.6 mn SMEs, and credit access to over 30 mn underserved With the inclusion principle integrated into main innovation projects, Ant International now links 2 bn user accounts with 150 mn merchants through multi-layered partnerships, provides global account services to 1.6 mn SMEs, and helps over 30 mn underserved businesses and individuals access quality credit. As its global payment, global account and embedded finance services expand rapidly, it is accelerating investments in compliance capabilities and advanced security technologies to tackle evolving regulatory and risk environments. From basketball courts in New York to marine protection in Java Indonesia, we build extensive partnerships to protect the environment and empower local communities. Ant International, a leading global digital payment, digitisation and financial technology provider, today published its 2025 Sustainability Report, the 2nd since the Company began independent
Dryad Launches Gen-4-Pro Silvanet Wildfire Sensor, Setting New Standard in Ultra-Early Fire Detection11.5.2026 11:09:00 CEST | Press release
Next-generation technology delivers unmatched detection speed, accuracy, and connectivity for global wildfire prevention Dryad Networks, a global leader in ultra-early wildfire detection technology, today announced the launch and immediate availability of the Gen-4-Pro Silvanet Wildfire Sensor, the fourth generation of its industry-leading Silvanet solution. The new Gen-4-Pro sensor introduces significant advancements in detection capability, energy autonomy, and connectivity—further strengthening Dryad’s mission to protect forests, infrastructure, and communities from the growing threat of wildfires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260510819235/en/ Silvanet Wildfire Sensor Gen4Pro enables ultra-early wildfire detection and environmental data monitoring. The Silvanet suite is a comprehensive wildfire detection system combining solar-powered gas sensors, a large-scale wireless IoT network, and cloud-based analy
Macnica ATD Europe Acquires Indesmatech to Deepen Engineering Presence Across Northern Europe11.5.2026 11:00:00 CEST | Press release
Strategic acquisition strengthens Macnica ATD Europe’s early-stage engagement, engineering support and coverage across Scandinavia and Northern Europe. Macnica ATD Europe today announced the acquisition of Indesmatech, a pan-European technology and advisory company specializing in advanced semiconductor representation, design-in support and consulting, as well as point click buying services. The acquisition is a strategic move by Macnica ATD Europe to strengthen its commercial and engineering presence across Scandinavia and Northern Europe, adding established regional relationships, in-house engineering capabilities and a proven ecosystem-led approach in line with its already strong presence in the region. It’s business focus areas include IoT, communications and power, embedded computing, memory and ASIC, and audio and sensing applications. This complements Macnica ATD Europe’s existing portfolio and reinforces its ability to support customers across a wide range of technology-driven
New Summer Program from Corona Invites the World to Experience “This Is Living”11.5.2026 10:00:00 CEST | Press release
The brand moves from inspiration to action with “Living Is Calling,” a campaign to enjoy the outdoors through a global partnership with Tripadvisor Today, Corona, the world’s most valuable beer brand*, unveils “Living is Calling” – a new global call to action inviting consumers to step outside and live life to the fullest this summer. As a powerful extension of its “This Is Living” platform, the new campaign invites the world to put living first through a partnership with Tripadvisor featuring over 300,000 experiences, and a new global film. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511429135/en/ “For the past 100 years, Corona has inspired the world to come outside and feel more moments of ‘This Is Living,’ and we believe the next chapter is about helping people take action and embrace the outdoors,” said Clarissa Pantoja, Global Vice President of Corona. “‘Living is Calling’ is our worldwide call to action, and we’
Braskem Celebrates Naming of Beautiful Future and Blooming Future, Next‑Generation Tankers for Cleaner Global Trade11.5.2026 10:00:00 CEST | Press release
Beautiful Future and Blooming Future combine cutting‑edge efficiency and emissions‑reduction technologies to support more responsible global trade. Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK), the largest polyolefins producer in the Americas and global leader in the production of biopolymers on an industrial scale announces today that Braskem Trading & Shipping (BT&S) has reached a major milestone in its fleet modernization and sustainability journey with the naming of Beautiful Future and Blooming Future, next‑generation chemical and product oil tankers designed to move essential raw materials more efficiently and with a significantly lower environmental footprint. Both vessels were formally named at a ceremony in China on May 8. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511112306/en/ Beautiful Future Beautiful Future and Blooming Future are LR1 (Long Range 1) vessels that will transport naphtha,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom